Gillespie Robinson & Grimm Inc. decreased its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 11.7% during the first quarter, according to its most recent filing with the SEC. The firm owned 7,679 shares of the biopharmaceutical company’s stock after selling 1,020 shares during the period. Gillespie Robinson & Grimm Inc.’s holdings in Bristol-Myers Squibb were worth $366,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently modified their holdings of BMY. Legal & General Group Plc lifted its holdings in shares of Bristol-Myers Squibb by 5.9% during the 4th quarter. Legal & General Group Plc now owns 8,568,445 shares of the biopharmaceutical company’s stock valued at $445,300,000 after buying an additional 474,820 shares during the period. Chescapmanager LLC increased its stake in shares of Bristol-Myers Squibb by 22.1% in the 4th quarter. Chescapmanager LLC now owns 361,755 shares of the biopharmaceutical company’s stock worth $18,804,000 after purchasing an additional 65,367 shares in the last quarter. Phocas Financial Corp. purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth $73,000. CSat Investment Advisory L.P. increased its stake in shares of Bristol-Myers Squibb by 13.6% in the 4th quarter. CSat Investment Advisory L.P. now owns 2,135 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 255 shares in the last quarter. Finally, Trust Co. of Virginia VA increased its stake in shares of Bristol-Myers Squibb by 105.7% in the 4th quarter. Trust Co. of Virginia VA now owns 50,048 shares of the biopharmaceutical company’s stock worth $2,601,000 after purchasing an additional 25,712 shares in the last quarter. 74.09% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts have recently commented on BMY shares. BMO Capital Markets upped their price objective on Bristol-Myers Squibb from $62.00 to $63.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 17th. Zacks Investment Research lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Friday, February 22nd. Bank of America set a $53.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Friday, January 25th. ValuEngine lowered Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 4th. Finally, Argus lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price target for the company. in a research note on Monday. One research analyst has rated the stock with a sell rating, nine have given a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $56.88.
Shares of NYSE:BMY traded up $0.31 during trading on Wednesday, reaching $47.74. The company’s stock had a trading volume of 8,758,808 shares, compared to its average volume of 18,652,727. The company has a current ratio of 1.93, a quick ratio of 1.79 and a debt-to-equity ratio of 0.37. Bristol-Myers Squibb Co has a 12 month low of $44.30 and a 12 month high of $63.69. The company has a market cap of $77.58 billion, a price-to-earnings ratio of 11.99, a PEG ratio of 2.19 and a beta of 0.77.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 EPS for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.01. The firm had revenue of $5.92 billion during the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. The firm’s revenue for the quarter was up 14.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.94 EPS. As a group, equities analysts forecast that Bristol-Myers Squibb Co will post 4.18 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were paid a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 3.44%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is currently 41.21%.
In other news, insider Karen Murphy Santiago sold 3,065 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $47.56, for a total transaction of $145,771.40. Following the transaction, the insider now directly owns 3,066 shares of the company’s stock, valued at $145,818.96. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Theodore R. Samuels II bought 5,000 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, May 16th. The shares were bought at an average cost of $47.29 per share, for a total transaction of $236,450.00. Following the completion of the transaction, the director now owns 27,000 shares of the company’s stock, valued at approximately $1,276,830. The disclosure for this purchase can be found here. 0.12% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Gillespie Robinson & Grimm Inc. Has $366,000 Holdings in Bristol-Myers Squibb Co (NYSE:BMY)” was first reported by Sundance Herald and is the sole property of of Sundance Herald. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://sundanceherald.com/2019/05/22/bristol-myers-squibb-co-bmy-stake-lessened-by-gillespie-robinson-grimm-inc.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.